Clinical trials: Hematologic Malignancy
Multiple Myeloma and Plasma Cell Neoplasm, Neurotoxicity
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
RATIONALE: Bortezomib and thalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. Bortezomib may also stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00792142
- Testing
- bortezomib, dexamethasone, melphalan
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- City of Hope Medical Center
Hematologic Malignancies, Relapse
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
The investigators hypothesize that adding carfilzomib to standard conditioning regimen for allo-HCT for advanced or high-risk hematologic malignancies will decrease post-transplant relapse and treatment-related mortality by…
- Conditions
- Hematologic Malignancies, Relapse, Graft-Versus-Host Disease
- Trial name
- NCT02145403
- Testing
- Carfilzomib, Tacrolimus
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Michigan Rogel Cancer Center
Leukemia, Myeloid, Acute
A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS
This is a Phase 1, open label, two-part study to determine recommended phase 2 dose (RP2D) and schedule of GSK3745417 administration in participants with relapsed/refractory AML or HR-MDS.
- Trial name
- NCT05424380
- Testing
- GSK3745417
- Where
- 10 sites in Canada, Germany and 3 more
- Volunteers
- 18 people
- Sponsor
- GlaxoSmithKline
ALL, B Cell Lymphoma
Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
Background: Although progress has been made in treating children with B-cell cancers such as leukemia or lymphoma, many children do not respond to the standard treatments.
- Conditions
- ALL, B Cell Lymphoma, Leukemia, Large Cell Lymphoma
- Trial name
- NCT01593696
- Testing
- Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Cardiomyopathy Due to Anthracyclines
Stem Cell Injection in Cancer Survivors
The primary purpose of this study is to examine the safety and feasibility of delivering allogeneic human mesenchymal stem cells (allo-MSCs) by transendocardial injection to cancer survivors with left ventricular (LV) dysfunction…
- Trial name
- SENECA (NCT02509156)
- Testing
- Allo-MSCs
- Where
- 7 sites in United States
- Volunteers
- 46 people
- Sponsor
- The University of Texas Health Science Center, Houston
Cancer of the Liver, Liver Cancer
IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
The working hypothesis is that oral administration of an attenuated strain of Salmonella typhimurium is safe and efficacious for patients with unresectable hepatic metastasis from a solid tumor cancer.
- Conditions
- Cancer of the Liver, Liver Cancer, Hepatoma, Liver Neoplasms
- Trial name
- NCT01099631
- Testing
- Salmonella typhimurium
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Multiple Myeloma, Plasma Cell Myeloma
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
RATIONALE: Drugs used in chemotherapy such as melphalan work in different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00064337
- Testing
- filgrastim, cyclophosphamide, dexamethasone
- Where
- 35 sites in United States
- Volunteers
- 104 people
- Sponsor
- SWOG Cancer Research Network
Bone Metastases, Multiple Myeloma
ExAblate (MRgFUS) Treatment of Metastatic Bone Tumors for the Palliation of Pain
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone and Multiple Myeloma Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
- Trial name
- NCT00656305
- Testing
- ExAblate MRfFUS
- Where
- 14 sites in United States, Canada and 3 more
- Volunteers
- 147 people
- Sponsor
- InSightec
Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
This is a Phase I study with a conditional cohort expansion phase to evaluate the feasibility of, and to obtain preliminary efficacy data about, pretreatment with Azacytidine (AZA) for 5 days followed by fludarabine/cytarabine…
- Trial name
- NCT01861002
- Testing
- Azacytidine, Fludarabine, Cytarabine
- Where
- 23 sites in United States, Australia and 1 more
- Volunteers
- 15 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Chronic Lymphocytic Leukemia
FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients
The purpose of this study is to provide treatment for patients who have chronic lymphocytic leukemia (CLL), and to compare the use of rituximab added to fludarabine+cyclophosphamide (FC) with FC alone, to determine if rituximab…
- Trial name
- NCT00090051
- Testing
- Rituximab, Fludarabine Phosphate, Cyclophosphamide
- Where
- 106 sites in United States, Australia and 15 more
- Volunteers
- 552 people
- Sponsor
- Hoffmann-La Roche
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation
This study will test the combination of clofarabine, cytarabine, and thymoglobulin as a non-myeloablative conditioning regimen for patients with myelodysplastic syndromes or acute myeloid leukemia undergoing allogeneic stem cell…
- Trial name
- NCT00593645
- Testing
- Clofarabine, Cytarabine, Thymoglobulin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Washington University School of Medicine
Leukemia, Lymphoma
Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer
RATIONALE: Pentostatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and mitoxantrone, work in different ways to stop the growth…
- Trial name
- NCT00546377
- Testing
- filgrastim, pegfilgrastim, rituximab
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Myeloproliferative Neoplasm
Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients
This study assesses the potential of using a TGFβ receptor inhibitor for the treatment of anemic patients with myeloproliferative neoplasms.
- Trial name
- NCT04103645
- Testing
- Vactosertib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Weill Medical College of Cornell University
Solid Tumors
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with…
- Trial name
- NCT02711137
- Testing
- INCB057643, Gemcitabine, Paclitaxel
- Where
- 18 sites in United States, Belgium and 1 more
- Volunteers
- 137 people
- Sponsor
- Incyte Corporation
Leukemia, Acute Myelogenous (AML), Leukemia, Acute Lymphocytic (ALL)
Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood
Background: Most patients with acute lymphoblastic leukemia (ALL) and many patients with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and non-Hodgkin's lymphoma (NHL) have a protein called Wilm's Tumor 1…
- Conditions
- Leukemia, Acute Myelogenous (AML), Leukemia, Acute Lymphocytic (ALL), Leukemia, Chronic Myelogenous (CML), Myelodysplastic Syndrome (MDS)
- Trial name
- NCT00923910
- Testing
- WT1 Peptide-Pulsed Dendritic Cells, Donor Lymphocytes, IL-4
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Myelodysplastic Syndromes, Hodgkin's Lymphoma
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
Background: In allogeneic stem cell transplantation (SCT), stem cells are taken from a donor and given to a recipient. Sometimes the recipient's immune system destroys the donors' cells.
- Conditions
- Myelodysplastic Syndromes, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Acute Leukemia
- Trial name
- NCT02356159
- Testing
- Rituximab, Conditioning chemotherapy, TMS
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Waldenstrom Macroglobulinemia, DASATINIB
Dasatinib In Waldenström Macroglobulinemia
This is Phase I pilot, single center study designed to explore the safety of Dasatinib in symptomatic Waldenström Macroglobulinemia participants who are progressing on ibrutinib therapy with BTK Cys481 or PLCG2 mutations
- Trial name
- NCT04115059
- Testing
- Dasatinib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Jorge J. Castillo, MD
Anemia, Chronic Lymphocytic Leukemia
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This phase III trial studies ibrutinib and rituximab to see how well they work compared to fludarabine phosphate, cyclophosphamide, and rituximab in treating patients with untreated chronic lymphocytic leukemia or small…
- Conditions
- Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- NCT02048813
- Testing
- Cyclophosphamide, Fludarabine Phosphate, Ibrutinib
- Where
- 781 sites in United States
- Volunteers
- 529 people
- Sponsor
- National Cancer Institute (NCI)
Myelodysplastic Syndrome
Study of LBH589 for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
The goal of this clinical research study is to learn if LBH589 can help to control lower-risk (low or intermediate-1 risk) MDS. The safety of this drug will also be studied.
- Trial name
- NCT00939159
- Testing
- LBH589
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Leukemia, Hodgkin Lymphoma
Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma or Leukemia
Researchers at St. Jude Children's Research Hospital want to investigate the feasibility of a yoga intervention for adolescents receiving treatment for lymphoma or leukemia.
- Conditions
- Leukemia, Hodgkin Lymphoma, Lymphoma, Non-Hodgkin's
- Trial name
- NCT02473523
- Testing
- PedsQL Cancer Module, PedsQL Multidimensional Fatigue Scale, Biodex System 3 Dynamometer
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- St. Jude Children's Research Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.